Development of a DHA-Losartan hybrid as a potent inhibitor of multiple pathway-induced platelet aggregation

Tsiailanis, Antonis D.; Vrettos, Eirinaios I.; Choleva, Maria; Kiriakidi, Sofia; Ganai, Ab Majeed; Patha, Tabasum Khan; Karpoormath, Rajshekhar; Mavromoustakos, Thomas; Fragopoulou, Elizabeth; Tzakos, Andreas G.

doi:10.1080/07391102.2021.1996461

Journal of Biomolecular Structure and Dynamics

2021

DOI: 10.1080/07391102.2021.1996461

|View full text |Cite

Development of a DHA-Losartan hybrid as a potent inhibitor of multiple pathway-induced platelet aggregation

Antonis D. Tsiailanis

Eirinaios I. Vrettos

Maria Choleva

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Exploring Hypertension: The Role of AT1 Receptors, Sartans, and Lipid Bilayers

Georgiou,

Chontzopoulou,

Routsi

et al. 2024

ACS Omega

View full text Add to dashboard Cite

The rational design of AT1 receptor antagonists represents a pivotal approach in the development of therapeutic agents targeting cardiovascular pathophysiology. Sartans, a class of compounds engineered to inhibit the binding and activation of Angiotensin II on the AT1 receptor, have demonstrated significant clinical efficacy. This review explores the multifaceted role of sartans in mitigating hypertension and related complications. We highlight the integration of crystallography, computational simulations, and NMR spectroscopy to elucidate sartan-AT1 receptor interactions, providing a foundation for the next-generation antagonist design. The review also delves into the challenges posed by the high lipophilicity and suboptimal bioavailability of sartans, emphasizing advancements in nanotechnology and novel drug delivery systems. Additionally, we discuss the impact of lipid bilayers on the AT1 receptor conformation and drug binding, underscoring the importance of the lipidic environment in receptor-drug interactions. We suggest that optimizing drug design to account for these factors could enhance the therapeutic potential of AT1 receptor antagonists, paving the way for improved cardiovascular health outcomes.

show abstract

Exploring Hypertension: The Role of AT1 Receptors, Sartans, and Lipid Bilayers

Georgiou,

Chontzopoulou,

Routsi

et al. 2024

ACS Omega

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Development of a DHA-Losartan hybrid as a potent inhibitor of multiple pathway-induced platelet aggregation

Cited by 1 publication

References 68 publications

Exploring Hypertension: The Role of AT1 Receptors, Sartans, and Lipid Bilayers

Exploring Hypertension: The Role of AT1 Receptors, Sartans, and Lipid Bilayers

Contact Info

Product

Resources

About